Age: 24
Height: 5'10"
Sex: M
Weight: 173lbs pre

Pre Day 26 Range
BUN: 14 17 (7-18)
ALT: 31 53 (10-60)
AST: 23 37 (10-43)
Cholesterol: 126.0 138.5 (0.0-200.0)
Triglycerides: 29 69 (35-160)
HDL: 39.0 33.1 (29.0-85.0)
LDL: 83.4 99.4 (65-131.0)
Dosing protocol: 30mg Havoc for 4 weeks.

Other supplements: 5g Fish oil, AST 32x multi, 5g Beta-alanine, AI Cycle Support 2x day, perhaps some other items

PCT: Nolva, dhea, Cycle support 2x day, 6-oxo

At day 30 the subject's weight was 186 which equates to a 13lb increase with minimal bodyfat increase. 17 days into PCT weight is 184lb. I'm springing for bloodwork as the individual is a close friend and I was interested to see what toxicity there was. Not has harsh as M1T or SD but far from benign. This was the subject's first experience using any ph/ps/steroid product. And in a bit of irony or confusion he bought 2 bottles of RPN's DCP thinking it would minimize the negatives associated with 17aa steroids. I told him how it was necessary to take certain supplement as damage control and hence his confusion. DCP was not used though. I will try to get him another panel a couple weeks after PCT but recent events have put me $13k in the hole and hence my recent absence.

I never meant to imply that RPN was putting forth such claims on toxicity. I'm not sure where the claims even started but I've seen numerous people allude to the fact that Havoc/Epistane has little if 'toxicity' on liver or cholesterol values even though it is 17aa. Some go so far as to claim it is indeed benign in this regard and no ancillary supps are necessary. The bloodwork above, albeit of only one individual, shows relatively low toxicity in comparison to other 17aa but still a cause for potential concern.

30mg spread throughout the day even on workout days. He's lifts in the morning so likely 30-45 mins pre. And subsequent doses at 6 hour intervals.
As for the blood results it was a complete panel, I only listed the values that had a >5% change. If he still has the results I will try to post the entire panel.
But now there's another guy who is going to run this and he's 5'3" 135. He's deadset to run the whole bottle so it's either 30mg for 30days or 20mg for 45 days. I suggested 20mg for 30 but it has to be the full bottle, so any recommendations given the low bodyweight? Is 6 weeks too long for a 17aa steroid? He's not under my guidance or direction so no bloodwork, but I would like to suggest a dosing protocol.

1: AIDS. 2003 Mar 28;17(5):699-710.Click here to read Links
Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting.

* Hengge UR,
* Stocks K,
* Wiehler H,
* Faulkner S,
* Esser S,
* Lorenz C,
* Jentzen W,
* Hengge D,
* Goos M,
* Dudley RE,
* Ringham G.

STD-Unit, Department of Dermatology and Venerology, University of Essen, Germany. ulrich.hengge@uni-duesseldorf.de

BACKGROUND: Despite highly active antiretroviral therapy (HAART), chronic involuntary weight loss still remains a serious problem in the care of HIV patients. Various alterations in energy metabolism and endocrine regulation have been found to cause loss of lean body mass (LBM) and body cell mass (BCM). Previous studies in HIV-positive men undergoing androgen replacement therapy or treatment with recombinant growth hormone (rGH) have shown partial restoration of LBM, but these treatments have largely been ineffective in eugonadal individuals. STUDY DESIGN: Double-blind, randomized, placebo-controlled trial of 89 HIV-positive women and men with wasting assigned to the anabolic steroid oxymetholone [50 mg twice (BID) or three times daily (TID)] or placebo for 16 weeks followed by open-label treatment. STUDY ENDPOINTS: Body weight, bioimpedance measurements, quality of life parameters and appetite. RESULTS: Oxymetholone led to a significant weight gain of 3.0 +/- 0.5 and 3.5 +/- 0.7 kg in the TID and BID groups, respectively (P < 0.05 for each treatment versus placebo), whereas individuals in the placebo group gained an average of 1.0 +/- 0.7 kg. Body cell mass increased in the oxymetholone BID group (3.8 +/- 0.4 kg; P < 0.0001) and in the oxymetholone TID group (2.1 +/- 0.6 kg; P < 0.005), corresponding to 12.4 and 7.4% of baseline BCM, respectively. Significant improvements were noted in appetite and food intake, increased well-being and reduced weakness by self-examination. The most important adverse event was liver-associated toxicity. Overall, 35% of patients in the TID, 27% of patients in the BID oxymetholone group and no patients in the placebo group had a greater than five times baseline increase for alanine aminotransferase during the double-blind phase of the study. CONCLUSIONS: Oxymetholone can be considered an effective anabolic steroid in eugonadal male and female patients with AIDS-associated wasting. The BID (100 mg/day) regimen appeared to be equally effective as the TID (150 mg/day) regimen in terms of weight gain, LBM and BCM and was associated with less, but still significant liver toxicity.

PMID: 12646793 [PubMed - indexed for MEDLINE]

At day 30 the subject's weight was 186 which equates to a 13lb increase with minimal bodyfat increase. 17 days into PCT weight is 184lb.